RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Dong Liang to Treatment Outcome

This is a "connection" page, showing publications Dong Liang has written about Treatment Outcome.
Connection Strength

0.115
  1. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X, Lu K. Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res. 2010 Dec 01; 70(23):9765-76.
    View in: PubMed
    Score: 0.070
  2. Liang S, Bian X, Liang D, Sivils JC, Neckers LM, Cox MB, Xie H. Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer. Pharm Dev Technol. 2016; 21(1):121-6.
    View in: PubMed
    Score: 0.023
  3. Meng QH, Xu E, Hildebrandt MA, Liang D, Lu K, Ye Y, Wagar EA, Wu X. Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome. Clin Chem. 2014 Jan; 60(1):222-32.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support